Icon

Accuneb - (Eq 0.021%, Base; Solution, Inhalation)

Albuterol Sulfate Mylan
Eq 0.021%, Base; Solution, Inhalation
Less Than $1000 mn
Less Than 5
Less Than 5
None None
Less Than 5
Less Than 5
AccuNeb is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease).
Yes
****** *** ******* *** ***** ** **** **** **. ****** ******** *** ******* ***** *** **** *********** ****** ** *** ***** *********. ******* *** *** ***** ********* *** ******** *** ******* ** ***** ****. ********* **** ***** **** **, *** ********* ***** ********** *** ***** *******. ** *** ******** *** ******** *** ******* ** ***** ****.
Accuneb Patent 1
****** *** *********
******* *** *********
********* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ *** [*** **** *********** *** *.***% ********] *** ********* *** ********* ******** ******** ** **** ****
******* *** \ ** *** ********* *** ********* ******** ******** ** ***** **, ****
********* ** \ ** ***** **, **** ******* ******** ************ ******** ** *** ****
  1. *** **, **** : ******* ******** ******** *** ** ** **** ******** *** *** **** *********** *** *.***% ********, ********* ** **** ** ***-*** *********** *******
  2. *** **, **** : ****** ******** ******** *** ** ** **** ******** *** *** **** *********** *** *.***% ********, ********* ** **** ** ***-*** *********** *******. *****://***.********.***/*******/********/******-***************-***-********-***-********-***-*******-*******-*-/
  3. *** *, **** : ********* ******** ***** ***** **'* **** ** ****** ** ****** ******* (*** **, ****)
  4. *** **, **** : ***** ***** * **** ******* ********* ** ****** ******* (*** **, ****)
  5. *** **, **** : ********** ********* **** *********, ***** *** ***** ** ********* *** *** *****
  6. *** **, **** : ********* ******** ***** ******** *** ******** *** *******.

Accuneb - (Eq, 0.042% base; solution, inhalation)

Albuterol Sulfate Mylan
Eq, 0.042% base; solution, inhalation
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
Less Than 5
Less Than 5
AccuNeb is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease).
Yes
******* ** ***** ** **** **** ** *** ****** *** ******* ***** *** **** *********** ****** ** *** ***** *********. ****** *** ***** **** **, *** ***** ********* *** ******** *** ******* ** *** ****. ********* **** ***** **** **, *** ********* ***** ********** *** ***** *******. ** *** ******** *** ******** *** ******* ** ***** ****.
Accuneb Patent 1
****** *** *********
******* *** *********
********* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** **\** ** *** ********* ******** ******** ** *** **, ****
******* *** \ *** [*** *** *********** *** *.***% ********] ** *** ********* ******** ******** ** *** **, ****
********* **\** ***** **, **** ******* ******** ************ ******** ** *** **, ****
  1. *** *, **** : * **** ** ** ***** *** ******* ** ******* *** *******
  2. *** **, **** : ******* ******** ******** *** ** ** **** ******** *** *** **** *********** *** *.***% **** ******** ** *** **** ** *** - **** *********** *******
  3. *** **, **** : ****** ******** ******** *** *.***% **** ********
  4. *** *, **** : ********* ******** ***** ** *** **** ** ****** ** ****** ******* (*** **, ****)
  5. *** **, **** : ***** ***** * **** ******* ********* ** ****** *******
  6. *** **, **** : ********** ********* **** ********* ***** ***** ** ********* *** *** *****
  7. *** **, **** : ********* ******** ******** *** *.***% **** ******** *** ******** *** *******

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.